Pulmatrix reports Q2 2026 results, cites progress on Eos SENOLYTIX merger
Cipla's Phase 3 plan for PUR1900 in India advances as Pulmatrix works toward closing its merger with Eos SENOLYTIX, expected in Q3 2026.
Pulmatrix, Inc. reported second quarter 2026 financial results on August 13, 2026 and gave an update on its pending merger with Eos SENOLYTIX, Inc., a privately held company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel platform.1 The company said it entered the merger agreement with Eos on March 26, 2026, with the deal currently anticipated to close in the third quarter of 2026, subject to customary closing conditions.1 Additional details on the merger were disclosed in a Form S-4 registration statement initially filed with the SEC on July 9, 2026, and amended on August 3, 2026.1
On the pipeline, Pulmatrix said its partner Cipla, which is developing PUR1900 outside the United States, wound down a Phase 2b trial with Pulmatrix in 2024, after which Cipla continued clinical development outside the U.S. and in 2025 completed its Phase 2 study in India, publishing positive results, and has since been approved by India's Central Drug Standard Control Organization to proceed with a Phase 3 trial that Cipla currently expects to begin in 2026.1 Under the existing arrangement, Pulmatrix would receive 2% royalties on any future net sales by Cipla outside the U.S., while inside the U.S. the companies share rights 50/50 and intend to seek other indications for the inhaled antifungal.1
Separately, Pulmatrix said its PUR3100 program for acute migraine has FDA acceptance of an IND application and a "study may proceed" letter allowing a Phase 2 study evaluating safety and preliminary efficacy in patients with acute migraine.1
Financially, research and development expenses were under $0.1 million for the three months ended June 30, 2026 and 2025, with all clinical development currently on hold while Pulmatrix works to license or monetize its clinical assets.1 Total cash and cash equivalents stood at $2.2 million as of June 30, 2026, plus $0.7 million in restricted cash to become unrestricted upon closing of the merger, down from $4.1 million at December 31, 2025.1 The company said its cash position is expected to be sufficient to fund operations at least through the anticipated closing of the Eos merger.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.